OS
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Richard F Schlenk, Pau Montesinos, Hee-Je Kim, Antonio Romero-Aguilar, Radovan Vrhovac, Elżbieta Patkowska, Pavel Žak, Po-Nan Wang, James Hanyok, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Arnaud Lesegretain, Jorge Cortes, Mikkael A Sekeres, Herve Dombret, Sergio Amadori, Jianxiang Wang, Alexander E Perl, Mark J Levis, Harry P Erba
Haematologica 110(9) 2024-2039
QuANTUM-First (ClinicalTrials.gov identifier: NCT02668653) was a randomized phase III trial in patients with newly diagnosed FLT3-internal tandem duplication (ITD)-positive acute myeloid leukemia (AML) treated with quizartinib or placebo plus standard induction and consolidation chemotherapy and/or allogeneic hematopoietic cell transplantation (allo-HCT), followed by single-agent maintenance therapy. We evaluated the impact of allo-HCT performed in first complete remission (CR1) or composite CR1 (CRc1) on overall survival (OS), considering treatment randomization. Post-hoc extended Cox regression multivariable analyses were conducted in patients who achieved complete remission/composite complete remission by the end of induction, including allo-HCT in CR1/CRc1 as a time-dependent variable to identify prognostic and predictive factors for OS. There were 297 patients with complete remission by the end of induction (quizartinib, N=147; placebo, N=150); of these, 157 (52.9%) underwent allo-HCT in CR1 (quizartinib, N=84; placebo, N=73). There were 368 patients with composite complete remission by the end of induction (quizartinib, N=192; placebo, N=176); of these, 196 (53.3%) underwent allo-HCT in CRc1 (quizartinib, N=110; placebo, N=86). Multivariable analyses revealed quizartinib treatment and allo-HCT in either CR1 (hazard ratio [HR]=0.553, 95% confidence interval [95% CI]: 0.383-0.798, P=0.0015 and HR=0.527, 95% CI: 0.349-0.796, P=0.0023, respectively) or CRc1 (HR=0.645, 95% CI: 0.470‒0.886, P=0.0068 and HR=0.557, 95% CI: 0.391-0.793, P=0.0012, respectively) as significant predictive factors for a longer OS. No new safety signals were identified. Patients who underwent protocol-specified allo-HCT in CR1/CRc1 experienced post-transplant-related complications, mostly grade ≥2 graft-versus-host disease, as expected. This post-hoc analysis further supports the use of quizartinib and allo-HCT in CR1/CRc1 as an efficacious and well-tolerated treatment strategy for newly diagnosed FLT3-ITD-positive AML patients fit for intensive chemotherapy.
2 个 Figure · 6 个 KM 面板
Figure 3. Kaplan-Meier plot of overall survival by treatment arm in patients who achieved complete remission (CR)/composite CR by the end of induction per independent review committee, by allogeneic hematopoietic cell transplantation in first CR/first composite CR. Post-hoc analysis. (A) The group of patients who underwent allogeneic hematopoietic cell transplantation (allo-HCT) a in first complete remission (CR1). (B) The group who did not undergo allo-HCT a in CR1. b (C) The group who underwent allo-HCT in first composite complete remission (CRc1). (D) The group who did not undergo allo-HCT in CRc1. b a Includes protocol-specified and non-protocol-specified allo-HCT. Some patients had both protocol-specified and non-protocol-specified allo-HCT. b Overall survival was censored at the starting date of the conditioning regimen for allo-HCT. OS: overall survival; HR: hazard ratio; 95% CI: 95% confidence interval; NR: not reached; NE: not evaluable; CRc1: first composite complete remission.
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel B
Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel C
Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel D
Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4. Time-dependent Simon and Makuch plot of overall survival from initial randomization by allogeneic hematopoietic cell transplantation in first complete remission (CR)/first composite CR in patients who achieved CR/composite CR by the end of induction per independent review committee. Post-hoc analysis. (A) The group who achieved CR by the end of induction. (B) The group who achieved composite CR by the end of induction. a “W/o allo-HCT in CR1” refers to patients who achieved CR without allogeneic hematopoietic cell transplantation (allo-HCT) in the study or patients who achieved CR with allo-HCT outside first CR. b “W/o allo-HCT in CRc1” refers to patients who achieved composite CR without allo-HCT in the study or patients who achieved composite CR with allo-HCT outside of first composite CR. OS: overall survival; CR1: first complete remission; CRc1: first composite complete remission; CRc: composite complete remission.
Figure 4 · Panel A
Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel B
Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。